News

MGCD0103 is an orally-administered, isotype-selective HDAC inhibitor. The compound is currently in one Phase I combination clinical trial with Taxotere for solid tumors, two Phase I/II combination trials

The two companies have formalized their desire to collaborate in a recent letter of intent, and are presently preparing the contractual details of their collaboration. They plan to

The company strongly believes that many fundamental aspects of Hologic and Suros’s ATEC line of breast biopsy systems infringe Tissue Extraction Devices’s US patent. The company is seeking

According to the commission, primate use is still necessary for vital pharmaceutical research programs in areas such as immune-based diseases, neurodegenerative disorders and infectious diseases. Of the 17

Under the terms of the five-year agreement, Akorn will be responsible for the manufacturing and supply of the ophthalmic drug product that will be manufactured at the company’s

The program, facilitated through local physicians in Southern California, will remotely monitor diabetic patients through the XTend Medical Disease Management Program. The patients will be able to take

The collaboration covers Evotec’s entire drug discovery offering, including its expertise in medicinal chemistry, biology and compound sourcing. Specifically, this includes biochemical and cellular assay development and high

Under the terms of the agreement, SSI has granted Sanofi pasteur a license to its technology with regard to the use of certain fusion proteins in the development

Based on the result of Qiagen’s initial research, the CMM may also provide laboratory-based genomics and proteomics services to assist Qiagen in the development and validation of new